Recently, single-nucleotide polymorphisms in the IL-16 gene have also correlated with increased serum levels of IL-16 in MS patients however, further studies in different populations are needed to establish this as a marker for genetic susceptibility [74]. This evidence concerns the gene IL16 and myeloid sarcoma.